Effect of bortezomib in combination with cisplatin and 5‑fluorouracil on 4T1 breast cancer cells

Burger AM and Seth AK: The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur J Cancer. 40:2217–2229. 2004. View Article : Google Scholar : PubMed/NCBI

Adams J: The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 4:349–360. 2004. View Article : Google Scholar : PubMed/NCBI

Combaret V, Boyault S, Iacono I, Brejon S, Rousseau R and Puisieux A: Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity. Mol Cancer. 7:502008. View Article : Google Scholar : PubMed/NCBI

Pei XY, Dai Y and Grant S: The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia. 17:2036–2045. 2003. View Article : Google Scholar

Yerlikaya A and Erin N: Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade. Int J Mol Med. 22:817–823. 2008.PubMed/NCBI

Boccadoro M, Morgan G and Cavenagh J: Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int. 5:182005. View Article : Google Scholar : PubMed/NCBI

Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, Adams J, Elliott P and Van Waes C: Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res. 7:1419–1428. 2001.PubMed/NCBI

LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, et al: Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 62:4996–5000. 2002.PubMed/NCBI

Denlinger CE, Rundall BK and Jones DR: Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. J Thorac Cardiovasc Surg. 128:740–748. 2004. View Article : Google Scholar

Teicher BA, Ara G, Herbst R, Palombella VJ and Adams J: The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res. 5:2638–2645. 1999.PubMed/NCBI

Freshney RI: Cytotoxicity. Culture of animal cells: a manual of basic techniques. 5th edition. Wiley-Liss; New Jersey, NJ: pp. 359–374. 2005

Chua BT, Lim SJ, Tham SC, Poh WJ and Ullrich A: Somatic mutation in the ACK1 ubiquitin association domain enhances oncogenic signaling through EGFR regulation in renal cancer derived cells. Mol Oncol. 4:323–334. 2010. View Article : Google Scholar : PubMed/NCBI

Yerlikaya A, Okur E and Ulukaya E: The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib. Tumour Biol. 33:1385–1392. 2012. View Article : Google Scholar : PubMed/NCBI

Basma H, El-Refaey H, Sgagias MK, Cowan KH, Luo X and Cheng PW: BCL-2 antisense and cisplatin combination treatment of MCF-7 breast cancer cells with or without functional p53. J Biomed Sci. 12:999–1011. 2005. View Article : Google Scholar : PubMed/NCBI

Hernandez-Vargas H, Ballestar E, Carmona-Saez P, von Kobbe C, Banon-Rodriguez I, Esteller M, Moreno-Bueno G and Palacios J: Transcriptional profiling of MCF7 breast cancer cells in response to 5-fluorouracil: relationship with cell cycle changes and apoptosis, and identification of novel targets of p53. Int J Cancer. 119:1164–1175. 2006. View Article : Google Scholar : PubMed/NCBI

Plano D, Baquedano Y, Ibanez E, Jimenez I, Palop JA, Spallholz JE and Sanmartin C: Antioxidant-prooxidant properties of a new organoselenium compound library. Molecules. 15:7292–7312. 2010. View Article : Google Scholar : PubMed/NCBI

Mimnaugh EG, Xu W, Vos M, Yuan X, Isaacs JS, Bisht KS, Gius D and Neckers L: Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther. 3:551–566. 2004.